Aarti Pharmalabs Ltd
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
- Market Cap ₹ 4,264 Cr.
- Current Price ₹ 471
- High / Low ₹ 485 / 235
- Stock P/E 22.5
- Book Value ₹ 183
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 13.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 174 days to 134 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|
0 | 1,200 | 1,945 | 1,855 | |
0 | 993 | 1,603 | 1,516 | |
Operating Profit | 0 | 207 | 342 | 339 |
OPM % | 17% | 18% | 18% | |
0 | 3 | 2 | 2 | |
Interest | 0 | 12 | 21 | 19 |
Depreciation | 0 | 42 | 63 | 68 |
Profit before tax | 0 | 155 | 261 | 255 |
Tax % | 21% | 26% | ||
0 | 122 | 193 | 189 | |
EPS in Rs | 21.35 | 20.91 | ||
Dividend Payout % | 0% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 62% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 59% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|
Equity Capital | 0 | 0 | 45 | 45 |
Reserves | -0 | 1,386 | 1,513 | 1,612 |
0 | 341 | 215 | 207 | |
0 | 312 | 457 | 449 | |
Total Liabilities | 0 | 2,040 | 2,231 | 2,313 |
0 | 782 | 926 | 1,006 | |
CWIP | 0 | 187 | 102 | 89 |
Investments | 0 | 32 | 74 | 81 |
0 | 1,038 | 1,130 | 1,137 | |
Total Assets | 0 | 2,040 | 2,231 | 2,313 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
0 | -44 | 263 | |
0 | -139 | -158 | |
0 | 260 | -163 | |
Net Cash Flow | 0 | 78 | -58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
Debtor Days | 115 | 83 | |
Inventory Days | 272 | 216 | |
Days Payable | 123 | 125 | |
Cash Conversion Cycle | 264 | 174 | |
Working Capital Days | 214 | 134 | |
ROCE % | 19% | 16% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Nov - Transcript of Earnings Conference Call for Q2 FY24 Financial Results held on November 9, 2023
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9 Nov - Audio recording of Earnings Conference Call of Financial Results for Q2/ H1 FY24
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Newspaper Publication of Audited Financial Results for Quarter and Half year ended September 30, 2023
- Announcement under Regulation 30 (LODR)-Investor Presentation 8 Nov
- Financial Results For The Quarter And Half Year Ended September 30, 2023 7 Nov
Annual reports
Concalls
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
Business Overview:[1]
Company is a Wholly Owned Subsidiary of Aarti Industries Limited. It develops Active Pharmaceutical Ingredients, New Chemical Entities, API intermediates, Regulatory Starting Materials, Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. It also provides stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.
Company has 6 manufacturing plants and 2 R&D centres.